What is Bal Pharma Ltd (BALPHARMA) share price return in the past 10 years?

Bal Pharma Ltd share price has declined -0.1% annually (CAGR) over the past ten years.

What is the share price of Bal Pharma Ltd (BALPHARMA)?

Company share prices are keep on changing according to the market conditions. The current trading price of Bal Pharma Ltd (BALPHARMA) on 10-Jun-2026 12:16:00 at 12:16 is 88.29.

What is the P/E ratio of Bal Pharma?

The latest standalone P/E ratio of Bal Pharma as of 10-Jun-2026 is 20.54.

What is the P/B ratio of Bal Pharma Ltd (BALPHARMA)?

The latest standalone P/B ratio of Bal Pharma Ltd (BALPHARMA) as of 10-Jun-2026 is 1.33.

What is the 52-week high and low of Bal Pharma Ltd (BALPHARMA)?

The 52-week high of Bal Pharma Ltd (BALPHARMA) is Rs. 112.97 and the 52-week low is Rs. 59.69.

Bal Pharma Ltd (BALPHARMA) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Bal Pharma Ltd (BALPHARMA)
Brand: Bal Pharma

Bal Pharma Ltd (BALPHARMA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524824 NSE: BALPHARMA Pharmaceuticals & Drugs | Small Cap | Bal Pharma Share Price

Bal Pharma Ltd (BALPHARMA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524824 NSE: BALPHARMA Pharmaceuticals & Drugs | Small Cap | Bal Pharma Share Price

Key Metrics

Valuation Multiples

Market Cap

₹139 Cr.

Current Price

₹88.3

52-Week Low / High

₹60 / 113

TTM EPS

₹4.2

TTM Sales

₹311 Cr.

Book Value per Share

₹65.4

P/E Ratio

20.54

Higher than its 5-year historical median

Industry PE

Price to Book (P/B)

1.33

Lower than its 5-year historical median

Price to Sales (P/S)

0.45

Lower than its 5-year historical median

EV/EBITDA

8.33

In line with its 5-year historical median

Dividend Yield

1.44%

Profitability Efficiency

Return on Equity (ROE)

8.17%

Underperforms industry median

Return on Capital Employed (ROCE)

9.69%

Underperforms industry median

Return on Assets (ROA)

2.28%

Operating Profit Margin

10%

Net Profit Margin

2.58%

Gross Profit Margin

5.1%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-10.65%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

25.96%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

0.91%

Asset Quality

Promoter Holding

50.86%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹88 Cr.

Equity

₹15.9 Cr.

Face Value

₹10

All Time Low / High

₹1.60 / 167.90

Bal Pharma stock performance

Key Ratios

Check Before You Invest

Quality

Not Good

Check detailed performance

Valuation

Undervalued

Check Valuation charts

Price Trend

Strong

Check Price chart

Q.1 Is Bal Pharma Ltd a good quality company?

Bal Pharma Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Bal Pharma Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Bal Pharma Ltd vs industry peers?

Bal Pharma Ltd revenue CAGR is 12.13%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Bal Pharma Ltd?

Promoters hold 50.86% of the Bal Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Bal Pharma Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -1.5% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	10.1%	12.8%	11.8%	10%	2.1%	12.6%	12.3%	10.4%	10.7%	9.7%	-
Value Creation Index ⓘ	-0.3	-0.1	-0.2	-0.3	-0.9	-0.1	-0.1	-0.3	-0.2	-0.3	-
Growth Parameters ⓘ
Sales ⓘ	198	226	208	223	171	249	280	303	339	303	311
Sales YoY Gr.	-	14.3%	-8.1%	7.4%	-23.5%	46.1%	12.5%	8.1%	11.7%	-10.7%	-
Adj EPS ⓘ	1.7	2.3	3.5	4.6	-6.6	7	4.4	4.5	5.3	4.8	4.2
YoY Gr.	-	41.8%	51.3%	29.7%	-243.6%	NA	-37.1%	1.1%	18.2%	-9.3%	-
BVPS (₹) ⓘ	42.5	47	51	54.2	46.5	52.9	57.7	60.3	58.3	62.1	65.4
Adj Net Profit ⓘ	2.1	3.3	5	6.5	-9.3	10.4	6.5	7	8.3	7.6	7
Cash Flow from Ops. ⓘ	1.3	6.4	12.6	11.6	21.7	10.2	30.6	5.4	28.5	20.3	-
Debt/CF from Ops. ⓘ	54.6	11.7	7.2	9.1	4.6	10.2	3.2	23.3	4.7	7.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	4.8%	12.1%	2.6%	-10.7%
Adj EPS ⓘ	12.5%	NA	2.7%	-9.3%
BVPSⓘ	4.3%	5.9%	2.5%	6.4%
Share Price	-0.1%	-1.9%	0.1%	-12.6%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	3.8	5.4	7.2	8.7	-13.1	14.3	7.8	7.6	8.8	7.9	6.7
Op. Profit Mgn % ⓘ	8.7	8.9	11	9.2	4.2	11.4	8.4	9.2	7.4	10	10.4
Net Profit Mgn % ⓘ	1.1	1.5	2.4	2.9	-5.5	4.2	2.3	2.3	2.5	2.5	2.2
Debt to Equity ⓘ	1.3	1.1	1.3	1.4	1.5	1.3	1.2	1.3	1.5	1.5	0.3
Working Cap Days ⓘ	211	221	290	303	386	270	273	296	270	290	153
Cash Conv. Cycle ⓘ	71	78	112	129	179	106	96	102	101	127	19

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	198	226	208	223	171	249	280	303	339	302
Operating Expenses ⓘ +	181	206	185	203	164	223	257	277	315	272
Manufacturing Costs	24	27	24	27	21	24	32	41	38	34
Material Costs	94	104	88	104	76	140	153	156	176	143
Employee Cost	36	41	50	48	49	40	44	52	60	62
Other Costs ⓘ	27	33	23	24	18	19	28	28	42	33
Operating Profit ⓘ	17	20	23	20	7	27	23	26	24	30
Operating Profit Margin (%)	8.7%	8.9%	11.0%	9.2%	4.1%	10.6%	8.4%	8.7%	7.1%	10.0%
Other Income ⓘ +	1	3	2	3	4	3	6	2	10	2
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	6	8	9	13	13	12	11	13	15	17
Depreciation ⓘ	7	6	7	6	7	7	7	7	10	10
Profit Before Tax ⓘ	5	9	8	4	-9	10	12	9	9	6
Tax ⓘ	2	3	3	-2	-0	1	3	2	2	-2
Profit After Tax	3	5	6	7	-9	9	9	6	8	8
PAT Margin (%)	1.4%	2.4%	2.9%	3.0%	-5.2%	3.7%	3.1%	2.0%	2.3%	2.6%
Adjusted EPS (₹)	2.2	3.8	4.2	4.8	-6.3	6.1	5.8	3.9	4.9	4.9
Dividend Payout Ratio (%)	45.90%	26.70%	23.90%	21%	0%	16.30%	17.30%	25.60%	24.60%	24.50%

Valuation of Bal Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	55	67	72	77	66	78	85	95	92	99
Share Capital ⓘ	13	14	14	14	14	15	15	16	16	16
Reserves ⓘ	42	52	58	63	52	64	71	79	76	83
Debt +	66	70	84	97	94	99	92	117	126	133
Long Term Debt	16	18	35	29	23	24	27	31	36	31
Short Term Debt	50	52	49	68	71	75	65	87	90	102
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	47	54	50	47	39	49	72	91	78	82
Others Liabilities ⓘ	26	29	45	36	40	36	40	45	38	37
Total Liabilities ⓘ	193	219	251	257	239	262	290	348	334	350
Fixed Assets
Net Fixed Assets ⓘ +	56	60	58	57	56	53	53	63	79	87
Gross Block	106	66	71	76	82	86	92	107	140	157
Accumulated Depreciation	50	6	13	19	26	33	39	44	61	70
CWIP ⓘ	4	2	0	0	0	0	1	0	0	3
Investments ⓘ	1	0	7	7	7	8	8	8	9	5
Inventories	42	54	66	70	68	60	74	98	88	103
Trade Receivables	57	61	64	66	52	69	78	95	102	95
Cash Equivalents	4	5	4	4	3	4	5	7	13	8
Others Assets ⓘ	29	37	51	53	53	67	70	76	43	50
Total Assets ⓘ	193	219	251	257	239	262	290	348	334	350

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	1	6	13	12	22	10	31	5	29	20
PBT ⓘ	5	9	8	4	-9	10	12	9	9	6
Adjustment ⓘ	11	15	15	16	17	17	14	19	22	25
Changes in Working Capital ⓘ	-14	-16	-10	-6	14	-17	6	-22	2	-8
Tax Paid ⓘ	-1	-1	-1	-2	-0	-0	-1	-1	-5	-2
Cash Flow From Investing Activity ⓘ +	-14	-8	-16	-12	-3	-7	-13	-22	-19	-15
Capex	-14	-8	-4	-5	-4	-3	-8	-15	-11	-19
Net Investments	0	0	0	-2	0	-1	-1	-1	-9	3
Others ⓘ	0	0	-12	-5	0	-3	-5	-7	1	1
Cash Flow From Financing Activity ⓘ +	12	2	4	0	-20	-3	-17	17	-7	-8
Net Proceeds from Shares ⓘ	0	0	0	0	0	3	0	4	1	1
Net Proceeds from Borrowing ⓘ	10	0	17	-5	-9	0	3	4	6	-5
Interest Paid ⓘ	-6	-8	-9	-12	-12	-12	-10	-12	-14	-17
Dividend Paid ⓘ	-2	-2	-2	-1	-1	0	-1	-2	-2	-2
Others ⓘ	10	12	-3	19	3	5	-8	23	2	15
Net Cash Flow ⓘ	-0	0	1	-0	-1	0	-0	0	3	-2

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	5.18	8.76	8.56	9.07	-12.47	12.61	10.47	6.8	8.27	8.17
ROCE (%)	10.07	12.77	11.76	9.95	2.09	12.57	12.28	10.4	10.7	9.69
Asset Turnover Ratio	1.13	1.13	0.89	0.88	0.69	1	1.02	0.95	0.99	0.88
PAT to CFO Conversion(x)	0.33	1.2	2.17	1.71	N/A	1.11	3.44	0.83	3.63	2.5
Working Capital Days
Receivable Days	92.10	92.70	108.80	106.20	125.50	88.70	95.90	104	106	118.70
Inventory Days	70	75.50	104.80	111	146.60	93.50	87.30	103.40	99.90	114.80
Payable Days	165.50	176.50	214.90	171.50	209.20	114.30	144.50	190.50	174.80	203.50

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bal Pharma Ltd FAQs

The current trading price of Bal Pharma on 10-Jun-2026 12:16 is ₹88.29.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 09-Jun-2026 the market cap of Bal Pharma stood at ₹138.7 Cr

The latest P/E ratio of Bal Pharma as of 09-Jun-2026 is 20.54.

The latest P/B ratio of Bal Pharma as of 09-Jun-2026 is 1.33.

The 52-week high of Bal Pharma is ₹113.0 and the 52-week low is ₹59.69.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bal Pharma is ₹311 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bal Pharma Ltd is a below average quality company.

The key valuation ratios of Bal Pharma Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Bal Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Bal Pharma Ltd

Bal Pharma Limited is a leading Indian Pharmaceutical Company with 25+ years of experience, specialized in Prescription Drugs, Generic & OTC Products, Intravenous Infusion and Bulk Actives.

The company strives hard to improve the quality of life for patients by providing them products that are Safe, Effective, High Quality and Affordable.

The company’s API and FDF are produced at world class manufacturing facilities. APIs are largely exported to Europe, Far East, Latin America, Africa, Middle East and other World markets. The FDF are exported to Semi-Regulated, Non-Regulated market and are now foraying to regulated market. The company is also one of the strong contenders for World Tender Business.

Business area of the company

The company is engaged in the manufacturing and selling of pharmaceutical products. The company caters to both domestic and international markets.

Business segments

API Intermediate: The company’s API (Active Pharmaceutical Ingredients) business began in 1996 with a simple objective of facilitating the manufacture of niche molecules that have been able to take the benefits of vertical integration to international and domestic markets. Bal Pharma’s API business has the competence and knowledge to undertake more than 30 different types of complex chemical reactions.

Finished formulations: Bal Pharma has a winning formula of cutting edge technology, handled by a highly qualified professional with a passion to deliver beyond excellence. The company is successfully exporting Finished Formulation to many countries. The company offers extensive range of products covering dosage forms - tablets, capsules, syrups, suspensions, IV infusions, Ophthalmic, creams and ointments to various Semi-Regulated markets.

Ayurveda/Herbal: Ayurveda is India’s traditional, natural system of medicine that has been practiced for more than 5,000 years. Ayurveda is a Sanskrit word that, when literally translated, means 'science of life' or 'practices of longevity.' Ayurveda provides an integrated approach to preventing and treating illness through lifestyle interventions and natural therapies. The company’s objective of providing “Good life to All” launched its Ayurvedic Division - Bal Vedics in 2003. Bal Vedics is dedicated to bringing out ‘nature’s best’ through International Quality Natural Formulations that combine traditional Indian Wisdom of medicine with Scientific Manufacturing.

Bal Pharma Ltd (BALPHARMA)

Bal Pharma Ltd (BALPHARMA)

Bal Pharma stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Bal Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bal Pharma Ltd FAQs

About Bal Pharma Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Bal Pharma Ltd (BALPHARMA)

Bal Pharma Ltd (BALPHARMA)

Bal Pharma stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Bal Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bal Pharma Ltd FAQs

What is the share price of Bal Pharma?

What is the market cap of Bal Pharma?

What is the P/E ratio of Bal Pharma?

What is the P/B ratio of Bal Pharma?

What is the 52-week high and low of Bal Pharma?

What is the TTM revenue of Bal Pharma?

Is Bal Pharma Ltd a good quality company?

Is Bal Pharma Ltd undervalued or overvalued?

Is Bal Pharma Ltd a good buy now?

About Bal Pharma Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.